254 related articles for article (PubMed ID: 32588916)
1. Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities.
Rodrigues DA; Pinheiro PSM; Sagrillo FS; Bolognesi ML; Fraga CAM
Med Res Rev; 2020 Nov; 40(6):2177-2211. PubMed ID: 32588916
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise.
Mai A; Rotili D; Valente S; Kazantsev AG
Curr Pharm Des; 2009; 15(34):3940-57. PubMed ID: 19751207
[TBL] [Abstract][Full Text] [Related]
3. Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases.
Han B; Wang M; Li J; Chen Q; Sun N; Yang X; Zhang Q
Eur J Med Chem; 2023 Oct; 258():115613. PubMed ID: 37399711
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?
De Simone A; Milelli A
ChemMedChem; 2019 Jun; 14(11):1067-1073. PubMed ID: 30958639
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Gediya P; Parikh PK; Vyas VK; Ghate MD
Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases.
Qiu X; Xiao X; Li N; Li Y
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jan; 72():60-72. PubMed ID: 27614213
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
9. Hybrid Histone Deacetylase Inhibitor: An Effective Strategy for Cancer Therapy.
Wu J; Nie J; Luan Y; Ding Y
Curr Med Chem; 2023; 30(20):2267-2311. PubMed ID: 36043742
[TBL] [Abstract][Full Text] [Related]
10. Current trends in development of HDAC-based chemotherapeutics.
Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
[TBL] [Abstract][Full Text] [Related]
11. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
Bai Y; Ahmad D; Wang T; Cui G; Li W
Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of HDACs--effective drugs against cancer?
Müller S; Krämer OH
Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases.
Sharma S; Sarathlal KC; Taliyan R
CNS Neurol Disord Drug Targets; 2019; 18(1):11-18. PubMed ID: 30289079
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of selective histone deacetylase 3 inhibition.
Zhang L; Chen Y; Jiang Q; Song W; Zhang L
Eur J Med Chem; 2019 Jan; 162():534-542. PubMed ID: 30472601
[TBL] [Abstract][Full Text] [Related]
15. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
16. HDAC Inhibitors: Innovative Strategies for Their Design and Applications.
Daśko M; de Pascual-Teresa B; Ortín I; Ramos A
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163980
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic application of histone deacetylase inhibitors for stroke.
Lv L; Tang YP; Han X; Wang X; Dong Q
Cent Nerv Syst Agents Med Chem; 2011 Jun; 11(2):138-49. PubMed ID: 21521169
[TBL] [Abstract][Full Text] [Related]
18. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
Peng X; Sun Z; Kuang P; Chen J
Eur J Med Chem; 2020 Dec; 208():112831. PubMed ID: 32961382
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
Xu X; Xie C; Edwards H; Zhou H; Buck SA; Ge Y
PLoS One; 2011 Feb; 6(2):e17138. PubMed ID: 21359182
[TBL] [Abstract][Full Text] [Related]
20. Advances in targeting histone deacetylase for treatment of solid tumors.
Shi MQ; Xu Y; Fu X; Pan DS; Lu XP; Xiao Y; Jiang YZ
J Hematol Oncol; 2024 May; 17(1):37. PubMed ID: 38822399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
